Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Approval Alert | Perioperative Nivolumab/Chemotherapy in Resectable NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
2
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
3
Debate Round 3: Timing of Treatment Initiation in LR-MDS (Earlier vs Delayed)
4
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
5
